DK2726865T3 - Fremgangsmåder til forudsigelse af levedygtighed for pattedyrsembryoner - Google Patents
Fremgangsmåder til forudsigelse af levedygtighed for pattedyrsembryoner Download PDFInfo
- Publication number
- DK2726865T3 DK2726865T3 DK12735601.2T DK12735601T DK2726865T3 DK 2726865 T3 DK2726865 T3 DK 2726865T3 DK 12735601 T DK12735601 T DK 12735601T DK 2726865 T3 DK2726865 T3 DK 2726865T3
- Authority
- DK
- Denmark
- Prior art keywords
- embryo
- cytoplasmic
- speed
- fertilization
- embryos
- Prior art date
Links
- 210000001161 mammalian embryo Anatomy 0.000 title claims description 141
- 238000000034 method Methods 0.000 title claims description 84
- 230000035899 viability Effects 0.000 title description 3
- 230000001086 cytosolic effect Effects 0.000 claims description 136
- 230000033001 locomotion Effects 0.000 claims description 128
- 210000002257 embryonic structure Anatomy 0.000 claims description 88
- 230000004720 fertilization Effects 0.000 claims description 73
- 210000004027 cell Anatomy 0.000 claims description 64
- 238000005259 measurement Methods 0.000 claims description 31
- 238000000917 particle-image velocimetry Methods 0.000 claims description 30
- 238000011161 development Methods 0.000 claims description 29
- 230000010349 pulsation Effects 0.000 claims description 29
- 230000015572 biosynthetic process Effects 0.000 claims description 26
- 238000000338 in vitro Methods 0.000 claims description 21
- 210000004292 cytoskeleton Anatomy 0.000 claims description 18
- 210000002459 blastocyst Anatomy 0.000 claims description 15
- 230000000737 periodic effect Effects 0.000 claims description 15
- 238000012546 transfer Methods 0.000 claims description 11
- 230000008774 maternal effect Effects 0.000 claims description 9
- 238000010191 image analysis Methods 0.000 claims description 7
- 230000032823 cell division Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 230000001360 synchronised effect Effects 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- 238000004891 communication Methods 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 94
- 235000013601 eggs Nutrition 0.000 description 61
- 210000000287 oocyte Anatomy 0.000 description 55
- 230000010355 oscillation Effects 0.000 description 31
- 230000018109 developmental process Effects 0.000 description 26
- 239000013598 vector Substances 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 108010043137 Actomyosin Proteins 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 21
- 238000003384 imaging method Methods 0.000 description 18
- 108010085238 Actins Proteins 0.000 description 17
- 102000007469 Actins Human genes 0.000 description 17
- 210000000805 cytoplasm Anatomy 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 14
- 108020004394 Complementary RNA Proteins 0.000 description 12
- 239000003184 complementary RNA Substances 0.000 description 12
- 238000006073 displacement reaction Methods 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 210000004508 polar body Anatomy 0.000 description 11
- 230000001052 transient effect Effects 0.000 description 11
- 108010077544 Chromatin Proteins 0.000 description 10
- 210000003483 chromatin Anatomy 0.000 description 10
- SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- GQWYWHOHRVVHAP-DHKPLNAMSA-N jaspamide Chemical compound C1([C@@H]2NC(=O)[C@@H](CC=3C4=CC=CC=C4NC=3Br)N(C)C(=O)[C@H](C)NC(=O)[C@@H](C)C/C(C)=C/[C@H](C)C[C@@H](OC(=O)C2)C)=CC=C(O)C=C1 GQWYWHOHRVVHAP-DHKPLNAMSA-N 0.000 description 8
- GQWYWHOHRVVHAP-UHFFFAOYSA-N jasplakinolide Natural products C1C(=O)OC(C)CC(C)C=C(C)CC(C)C(=O)NC(C)C(=O)N(C)C(CC=2C3=CC=CC=C3NC=2Br)C(=O)NC1C1=CC=C(O)C=C1 GQWYWHOHRVVHAP-UHFFFAOYSA-N 0.000 description 8
- 108010052440 jasplakinolide Proteins 0.000 description 8
- 210000004688 microtubule Anatomy 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 7
- 102000029749 Microtubule Human genes 0.000 description 7
- 108091022875 Microtubule Proteins 0.000 description 7
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 7
- 108010074596 Myosin-Light-Chain Kinase Proteins 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000001054 cortical effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000015887 sperm entry Effects 0.000 description 7
- 230000001960 triggered effect Effects 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 230000008521 reorganization Effects 0.000 description 6
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 5
- 229930012538 Paclitaxel Natural products 0.000 description 5
- MCEXQZRGUKALLT-VVEOGCPPSA-N acetyloxymethyl 2-[n-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[[6-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-2-[(e)-(5-oxo-2-sulfanylideneimidazolidin-4-ylidene)methyl]-1-benzofuran-5-yl]oxy]ethoxy]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=CC2=C1OC(\C=C\1C(NC(=S)N/1)=O)=C2 MCEXQZRGUKALLT-VVEOGCPPSA-N 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 210000002308 embryonic cell Anatomy 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 229950006344 nocodazole Drugs 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000005640 Myosin Type II Human genes 0.000 description 4
- 108010045128 Myosin Type II Proteins 0.000 description 4
- 108010009711 Phalloidine Proteins 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000013020 embryo development Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000013178 mathematical model Methods 0.000 description 4
- 230000003534 oscillatory effect Effects 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000001020 rhythmical effect Effects 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 229910001631 strontium chloride Inorganic materials 0.000 description 4
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 4
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 102000003505 Myosin Human genes 0.000 description 3
- 108060008487 Myosin Proteins 0.000 description 3
- CJGYSWNGNKCJSB-YVLZZHOMSA-M [(4ar,6r,7r,7ar)-6-[6-(butanoylamino)purin-9-yl]-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl] butanoate Chemical compound C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-M 0.000 description 3
- 230000031016 anaphase Effects 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000003632 microfilament Anatomy 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 210000004681 ovum Anatomy 0.000 description 3
- 230000001776 parthenogenetic effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- YJIYWYAMZFVECX-UHFFFAOYSA-N 2-[N-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]anilino]acetic acid acetyloxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O YJIYWYAMZFVECX-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- -1 Ca2+ ion Chemical class 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 238000003657 Likelihood-ratio test Methods 0.000 description 2
- 102000002151 Microfilament Proteins Human genes 0.000 description 2
- 108010040897 Microfilament Proteins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000011856 Utrophin Human genes 0.000 description 2
- 108010075653 Utrophin Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000010859 live-cell imaging Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000023439 meiosis II Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000000270 postfertilization Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 239000012109 Alexa Fluor 568 Substances 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 241000251557 Ascidiacea Species 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101150093612 GAP43 gene Proteins 0.000 description 1
- 241001481828 Glyptocephalus cynoglossus Species 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 241000282418 Hominidae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000867811 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1C Proteins 0.000 description 1
- 238000003744 In vitro fertilisation Methods 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 241000368289 Lepidosaphes ulmi Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 241000288935 Platyrrhini Species 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 102100032574 Voltage-dependent L-type calcium channel subunit alpha-1C Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 210000001771 cumulus cell Anatomy 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000023428 female meiosis Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 101150003286 gata4 gene Proteins 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000008009 mammalian fertilization Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D19/00—Instruments or methods for reproduction or fertilisation
- A61D19/04—Instruments or methods for reproduction or fertilisation for embryo transplantation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M21/00—Bioreactors or fermenters specially adapted for specific uses
- C12M21/06—Bioreactors or fermenters specially adapted for specific uses for in vitro fertilization
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/12—Means for regulation, monitoring, measurement or control, e.g. flow regulation of temperature
- C12M41/14—Incubators; Climatic chambers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/26—Means for regulation, monitoring, measurement or control, e.g. flow regulation of pH
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/46—Means for regulation, monitoring, measurement or control, e.g. flow regulation of cellular or enzymatic activity or functionality, e.g. cell viability
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Sustainable Development (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Physiology (AREA)
- Thermal Sciences (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Reproductive Health (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Claims (17)
1. In Wfro-fremgangsmåde til vurdering af udviklingspotentialet af et pattedyrsembryon, f.eks. et pattedyrsembryon, som er befrugtet in vitro, hvor fremgangsmåden omfatter (a) måling af cytoplasmatiske bevægelser i embryonet i den encellede tilstand, og eventuelt yderligere målinger af periodiske ændringer i formen af embryonet i den encellede tilstand, og (b) anvendelse af målingerne til at forudsige udviklingspotentialet af embryonet.
2. Fremgangsmåde ifølge krav 1, hvor (i) målingerne af cytoplasmatiske bevægelser er målinger af den gennemsnitlige cytoplasmatiske hastighed i det encellede embryon, eller (ii) de periodiske ændringer i formen af embryonet er pulsationer af befrugtningskeglen (FC-pulsationer).
3. Fremgangsmåde ifølge krav 2, hvor målingerne foretages over en tidsperiode, som er tilstrækkelig til at identificere to på hinanden følgende hastighedstoppunkter eller FC-pulsationer, og tidsintervallet mellem de hastighedstoppunkter eller FC-pulsationer beregnes, f.eks. hvor et længere interval eller et længere gennemsnitligt interval mellem hastighedstoppunkterne eller FC-pulsationerne korrelerer med en forudsigelse af et større udviklingspotentiale.
4. Fremgangsmåde ifølge krav 3, hvor udviklingspotentialet af embryonet forudsiges ved at sammenligne intervallet eller det gennemsnitlige interval mellem hastighedstoppunkterne eller FC-pulsationerne med en eller flere forudbestemte referenceværdier, f.eks. hvor hastighedstoppunkterne eller FC-pulsationerne er synkrone med Ca2+-transienter i embryonet.
5. Fremgangsmåde ifølge et hvilket som helst af kravene 2 til 4, hvor den gennemsnitlige cytoplasmatiske hastighed måles inden det første ha stighedstoppunkt, som registreres, mellem hastighedstoppunkter, og/eller efter det sidste registrerede hastighedstoppunkt, hvor den gennemsnitlige hastighed beregnes over tid, hvor denne er den gennemsnitlige basale cyto-plasmatiske hastighed, f.eks. hvor en hurtigere gennemsnitlig basal cyto-plasmatisk hastighed korrelerer med en forudsigelse af et større udviklingspotentiale, og eventuelt hvor udviklingspotentialet af embryonet forudsiges ved at sammenligne den gennemsnitlige basale cytoplasmatiske hastighed med én eller flere forudbestemte referenceværdier.
6. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor det enkeltcellede embryon er på et udviklingstrin mellem befrugtning og dannelse af forkernen, f.eks. hvor den encellede er på et udviklingstrin mellem befrugtning og regression af befrugtningskernen, f.eks. hvor pattedyrsembryonet er på et udviklingsniveau, hvor befrugtningskeglen er fuldt dannet, og eventuelt hvor forudsigelsen af udviklingspotentialet er baseret på målinger, der er foretaget i den periode, hvor befrugtningskeglen er til stede.
7. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor måltagningen omfatter optagelse af et tidsforløbsbillede, der efterfølges af en kvantitativ billedanalyse, f.eks. hvor billederne er optaget fra (i) et enkelt plan gennem det encellede embryon, (ii) et plan gennem midten af det encellede embryon, og/eller (iii) et plan, der gennemskærer befrugtningskeglen af det encellede embryon.
8. Fremgangsmåde ifølge krav 7, hvor embryonet er afbilledet, mens den holdes i en lille dråbe af medium, og eventuelt hvor embryonet er ét af en tæt gruppe af encellede celleembryoner i den lille dråbe af medium.
9. Fremgangsmåde ifølge krav 7 eller krav 8, hvor billedoptagelsen gennemføres inden for 4 timer efter befrugtning, f.eks. inden for 2 timer efter befrugtning.
10. Fremgangsmåde ifølge et hvilket som helst af kravene 7 til 9, hvor (i) den kvantitative billedanalyse anvender partikelbilledvelocimetri (PIV); og/eller (ii) hvor måltagningen er ikke-invasiv; og/eller (iii) hvor målingerne foretages i fravær af cytoplasmatisk farvestof i embryonet; og/eller (iv) hvor måltagningen ikke griber ind i funktionen af cytoskelettet; og/eller (v) hvor måltagningen ikke griber ind i dannelsen af befrugtningskeglen; og/eller (vi) hvor forudsigelse af udviklingspotentialet omfatter bestemmelse af muligheden for, at embryonet vil udvikles til blastocysttrinnet; og/eller (vii) hvor udviklingspotentialet omfatter hastigheden af celledelingen af embryonet i en efterfølgende kultur; og/eller (viii) hvor udviklingspotentialet omfatter antallet af celler i embryonet, som vil udvikles efter fire dage i en efterfølgende kultur; og/eller (ix) hvor forudsigelse af udviklingspotentialet omfatter bestemmelse af muligheden for, at embryonet vil udvikles fuldstændigt efter overførsel til en maternal modtager; og/eller (x) hvor fremgangsmåden gennemføres inden for 24 timer efter befrugtning; og/eller (xi) hvor fremgangsmåden gennemføres inden for 4 timer efter befrugtning; og/eller (xii) hvor kun målingerne af cytoplasmatiske bevægelser og/eller pulsationer af befrugtningskeglen i embryonet anvendes til at vurdere udviklingspotentialet af embryonet.
11. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor embryonerne kultiveres yderligere, og eventuelt hvor udviklingsomfanget og/eller morfologien af embryonet i kultur yderligere anvendes til at vurdere udviklingspotentialet af embryonet.
12. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor pattedyrsembryonet er (i) et ikke-humant pattedyrsembryon, (ii) et musseem-bryon, (iii) et kvægembryon, eller (iv) et menneskeligt embryon.
13. Fremgangsmåde til in Wiro-befrugtning, omfattende befrugtning af et pattedyrsæg og vurdering af udviklingspotentialet af det resulterende embryon ifølge fremgangsmåden ifølge et hvilket som helst af de foregående krav.
14. Fremgangsmåde til udvælgelse af et eller flere embryoner, der er egnet til anvendelse i en fremgangsmåde til assisteret reproduktion, fra en flerhed af embryoner, hvor fremgangsmåden omfatter vurdering af udviklingspotentialet af hvert embryon ifølge fremgangsmåden ifølge et hvilket som helst af kravene 1 til 12, og udvælgelse af et eller flere embryoner på basis af deres forud-sagte udviklingspotentiale.
15. Fremgangsmåde til klassificering af et eller flere embryoner i en population af embryoner ifølge et udviklingspotentiale, hvor fremgangsmåden omfatter vurdering af udviklingspotentialet af hvert embryon i populationen ifølge fremgangsmåden ifølge et hvilket som helst af kravene 1 til 12, og klassificering af hvert embryon på basis af dettes forudsagte udviklingspotentiale, og eventuelt yderligere udvælgelse af et eller flere embryoner, der er egnet til anvendelse i en fremgangsmåde til assisteret reproduktion, fra en flerhed af embryoner på basis af deres forudsagte udviklingspotentiale; f.eks. hvor tilstedeværelsen af et beregnet tidsinterval eller gennemsnitligt tidsinterval mellem hastighedstoppunkter eller FC-pulsationer, som er længere, f.eks. en halv standardafvigelse længere eller mindst én standardafvigelse længere, end det gennemsnitlige interval af populationen eller det gennemsnitlige tidsinterval mellem hastighedstoppunkter, og/eller tilstedeværelsen af en gennemsnitlig basal cytoplasmatisk hastighed, som er hurtigere, f.eks. en halv standardafvigelse hurtigere eller mindst én standardafvigelse hurtigere, end den gennemsnitlige cytoplasmatiske basale hastighed af po- pulationen, angiver, at et embryon har et højt udviklingspotentiale.
16. System til udførelse af fremgangsmåden ifølge et hvilket som helst af de foregående krav 1 til 12, hvor systemet omfatter en eller flere sensorer til optagelse af tidsforløbsbilleder af embryonerne og mindst én processor i kommunikation med den mindst én sensor, hvor processoren er programmeret med computerlæsbare instruktioner til at udføre fremgangsmåden ifølge et hvilket som helst af de foregående krav til at optage og omdanne billederne til en forudsigelse af udviklingspotentialet af embryonet.
17. System ifølge krav 16; (i) som omfatter et klimakammer til kontrol af temperaturen og/eller pH-eksposition af embryonet; (ii) som omfatter et opvarmet trin til kontrol af temperaturen af embryonet; og/eller (iii) hvor den ene eller flere sensorer er konfigureret til at anvende hvidt overført lys til at optage tidsforløbsbillederne.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161503827P | 2011-07-01 | 2011-07-01 | |
| US201161577860P | 2011-12-20 | 2011-12-20 | |
| PCT/GB2012/051533 WO2013005012A1 (en) | 2011-07-01 | 2012-06-29 | Methods for predicting mammalian embryo viability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2726865T3 true DK2726865T3 (da) | 2017-03-20 |
Family
ID=46514697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12735601.2T DK2726865T3 (da) | 2011-07-01 | 2012-06-29 | Fremgangsmåder til forudsigelse af levedygtighed for pattedyrsembryoner |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9410939B2 (da) |
| EP (1) | EP2726865B1 (da) |
| JP (1) | JP6105570B2 (da) |
| CN (1) | CN103703368A (da) |
| AU (1) | AU2012280031B2 (da) |
| CA (1) | CA2838819A1 (da) |
| DK (1) | DK2726865T3 (da) |
| ES (1) | ES2618831T3 (da) |
| WO (1) | WO2013005012A1 (da) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015192352A1 (zh) * | 2014-06-19 | 2015-12-23 | 湖南光琇高新生命科技有限公司 | 一种根据分裂行为对体外受精治疗胚胎进行评估的等级分类方法 |
| JP6746945B2 (ja) | 2015-06-30 | 2020-08-26 | ソニー株式会社 | 情報処理装置、情報処理システム及び情報処理方法 |
| US20170071516A1 (en) * | 2015-09-15 | 2017-03-16 | Samsung Electronics Co., Ltd. | Mobile optical device and methods for monitoring microvascular hemodynamics |
| JP6992748B2 (ja) * | 2016-06-15 | 2022-02-03 | ソニーグループ株式会社 | 情報処理装置、観察システム、観察方法及びプログラム |
| WO2018012353A1 (en) | 2016-07-13 | 2018-01-18 | Sony Corporation | Information processing device, information processing method, and information processing system |
| JP2018014991A (ja) | 2016-07-13 | 2018-02-01 | ソニー株式会社 | 情報処理装置、情報処理方法及び情報処理システム |
| JP2018022216A (ja) | 2016-08-01 | 2018-02-08 | ソニー株式会社 | 情報処理装置、情報処理方法、及びプログラム |
| US20190225923A1 (en) * | 2016-09-30 | 2019-07-25 | Nanyang Technological University | Apparatus for embryo biopsy |
| JP6834400B2 (ja) | 2016-11-22 | 2021-02-24 | ソニー株式会社 | 撮像素子、積層型撮像素子、撮像装置及び電子装置 |
| EP3550010A4 (en) * | 2016-11-30 | 2019-12-18 | Sony Corporation | INFORMATION PROCESSING DEVICE, OBSERVATION SYSTEM, INFORMATION PROCESSING METHOD AND PROGRAM |
| EP3812449A4 (en) * | 2018-06-20 | 2022-03-23 | JCR Pharmaceuticals Co., Ltd. | Analysis software and device for embryo selection |
| US11386559B2 (en) * | 2019-04-03 | 2022-07-12 | The Regents Of The University Of California | System and method for tissue viability screening |
| CA3144694A1 (en) | 2019-07-25 | 2021-01-28 | Jose A. Horcajadas | Identification of viable human embryos |
| CN111832191B (zh) * | 2020-07-29 | 2023-06-30 | 南开大学 | 基于生长域的微管内增量式细胞质速度场评估方法 |
| US20230342827A1 (en) * | 2022-04-21 | 2023-10-26 | Dmitri Dozortsev | Billing for successful ivf treatment |
| CN116223368B (zh) * | 2022-12-12 | 2025-12-12 | 北京航空航天大学 | 快速定位和观测培养皿内胚胎的系统和方法 |
| CN116482379A (zh) * | 2023-04-06 | 2023-07-25 | 中信湘雅生殖与遗传专科医院有限公司 | 用于诊断精子常规体外受精结果的方法、应用、装置、计算机设备和存储介质 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2528536A1 (en) * | 2003-06-06 | 2005-01-06 | Arborgen, Llc. | Transcription factors |
| DE602007004143D1 (de) | 2006-04-20 | 2010-02-25 | Northern Sydney And Central Co | Verfahren zur Beurteilung der Lebensfähigkeit von Embryos |
| US20100099135A1 (en) * | 2008-10-22 | 2010-04-22 | Mandy Katz-Jaffe | Methods and assays for assessing the quality of embryos in assisted reproduction technology protocols |
| PL2827150T3 (pl) * | 2009-08-22 | 2021-05-31 | The Board Of Trustees Of The Leland Stanford Junior University | Obrazowanie i ocena zarodków, oocytów i komórek macierzystych |
-
2012
- 2012-06-29 DK DK12735601.2T patent/DK2726865T3/da active
- 2012-06-29 CA CA2838819A patent/CA2838819A1/en not_active Abandoned
- 2012-06-29 WO PCT/GB2012/051533 patent/WO2013005012A1/en not_active Ceased
- 2012-06-29 EP EP12735601.2A patent/EP2726865B1/en not_active Not-in-force
- 2012-06-29 ES ES12735601.2T patent/ES2618831T3/es active Active
- 2012-06-29 AU AU2012280031A patent/AU2012280031B2/en not_active Ceased
- 2012-06-29 US US14/128,639 patent/US9410939B2/en not_active Expired - Fee Related
- 2012-06-29 JP JP2014517943A patent/JP6105570B2/ja not_active Expired - Fee Related
- 2012-06-29 CN CN201280033155.4A patent/CN103703368A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2726865B1 (en) | 2016-12-14 |
| US9410939B2 (en) | 2016-08-09 |
| ES2618831T3 (es) | 2017-06-22 |
| JP2014520522A (ja) | 2014-08-25 |
| AU2012280031A1 (en) | 2014-01-16 |
| JP6105570B2 (ja) | 2017-03-29 |
| CN103703368A (zh) | 2014-04-02 |
| US20140206931A1 (en) | 2014-07-24 |
| WO2013005012A1 (en) | 2013-01-10 |
| CA2838819A1 (en) | 2013-01-10 |
| AU2012280031B2 (en) | 2016-12-15 |
| EP2726865A1 (en) | 2014-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2726865T3 (da) | Fremgangsmåder til forudsigelse af levedygtighed for pattedyrsembryoner | |
| Ajduk et al. | Rhythmic actomyosin-driven contractions induced by sperm entry predict mammalian embryo viability | |
| Nozawa et al. | Sperm-borne phospholipase C zeta-1 ensures monospermic fertilization in mice | |
| Scheffler et al. | Two mechanisms drive pronuclear migration in mouse zygotes | |
| Li et al. | The road to maturation: somatic cell interaction and self-organization of the mammalian oocyte | |
| Alarcon | Cell polarity regulator PARD6B is essential for trophectoderm formation in the preimplantation mouse embryo | |
| Werner et al. | Using Xenopus skin to study cilia development and function | |
| Schatten et al. | The functional significance of centrosomes in mammalian meiosis, fertilization, development, nuclear transfer, and stem cell differentiation | |
| Ajduk et al. | The basal position of nuclei is one pre-requisite for asymmetric cell divisions in the early mouse embryo | |
| Bavister | The mammalian preimplantation embryo: regulation of growth and differentiation in vitro | |
| Baldwin et al. | Global analysis of cell behavior and protein dynamics reveals region-specific roles for Shroom3 and N-cadherin during neural tube closure | |
| Iyer et al. | Delay of human early development via in vitro diapause | |
| Kryzak et al. | Prophase I mouse oocytes are deficient in the ability to respond to fertilization by decreasing membrane receptivity to sperm and establishing a membrane block to polyspermy | |
| Gilbert et al. | Genetic mouse embryo assay: improving performance and quality testing for assisted reproductive technology (ART) with a functional bioassay | |
| Clayton et al. | Cell surface localisation and stability of uvomorulin during early mouse development | |
| Meng et al. | Role of Src homology 2 domain-mediated PTK signaling in mouse zygotic development | |
| Nowotschin et al. | Imaging mouse development with confocal time-lapse microscopy | |
| Plusa et al. | Cell fate in mammalian development | |
| Tielens et al. | Real‐time recordings of migrating cortical neurons from GFP and Cre recombinase expressing mice | |
| Liu et al. | Early patterning of cloned mouse embryos contributes to post-implantation development | |
| Shi et al. | Opposing actomyosin pools generate cortical flows that establish epithelial polarity | |
| Kratschke | Investigating PSD-95 turnover at the synapse using the HaloTag technology | |
| Branca | The Membrane Block to Polyspermy in Mammalian Eggs; Analyses of Calcium Signaling and Actin Dynamics During Fertilization | |
| Combelles et al. | Determinants of oocyte quality: impact on in vitro fertilization failures | |
| Gonçalves et al. | Rapid and simple method for in vivo ex utero development of mouse embryo explants |